OConnell Daniel Joseph

Chief Executive Officer

OConnell Daniel Joseph has filed 4 SEC Form 4 filings (9 transaction rows) across 1 company, with disclosures dating back to 2026. 4 of those filings fall inside the rolling window. Most recent filing: Jan 23, 2026.

On the most recent filing, OConnell Daniel Joseph is listed as Chief Executive Officer at Acumen Pharmaceuticals, Inc. Inside the rolling window, OConnell Daniel Joseph reported no open-market purchases and 8 open-market sales totaling $163K in ABOS. The largest disclosed transaction in the window is a sale of 37,755 ABOS shares on Jan 7, 2026, worth $75K.

Companies traded

Other insiders at ABOS

Insider Buying

$0

reported purchases (SEC code P)

Insider Selling

$163K

reported sales (SEC code S)

Companies

1

in the rolling window

Source
ABOSSale$17KJan 23SEC ↗
ABOSSale$5KJan 23SEC ↗
ABOSSale$15KJan 12SEC ↗
ABOSSale$23KJan 12SEC ↗
ABOSSale$9KJan 12SEC ↗
ABOSSale$9KJan 7SEC ↗
ABOSSale$10KJan 7SEC ↗
ABOSSale$75KJan 7SEC ↗
Showing 1–8 of 8
1 / 1

Frequently asked questions

How many SEC Form 4 filings has OConnell Daniel Joseph made?

OConnell Daniel Joseph has filed 4 SEC Form 4 filings (9 transaction rows) across 1 company since 2026.

Which companies does OConnell Daniel Joseph trade?

OConnell Daniel Joseph has filed SEC Form 4 disclosures for 1 company, including ABOS.

When was OConnell Daniel Joseph's most recent SEC Form 4 filing?

OConnell Daniel Joseph's most recent SEC Form 4 filing on Tracefour is dated Jan 23, 2026.

What is OConnell Daniel Joseph's job title?

On the most recent SEC Form 4 filings tracked by Tracefour, OConnell Daniel Joseph is listed as Chief Executive Officer.

What is OConnell Daniel Joseph's total buy and sell value in the current window?

Inside the rolling retention window, OConnell Daniel Joseph bought $0 and sold $163K based on SEC Form 4 filings.

What was OConnell Daniel Joseph's largest disclosed transaction?

The largest disclosed transaction in the current window is a sale of 37,755 ABOS shares on 2026-01-07, worth $75K, per SEC Form 4 filings.